NCT04969965View on ClinicalTrials.gov

To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 21, 2021

Primary Completion Date

October 7, 2021

Study Completion Date

October 7, 2021

Conditions
NSCLCHealthy VolunteersPharmacokinetics
Interventions
DRUG

aumolertinib

EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg

Trial Locations (2)

53095

Spaulding Clinical Research, West Bend

Unknown

New Zealand Clinical Research, Auckland

All Listed Sponsors
lead

EQRx, Inc.

INDUSTRY